Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2022 - 2025)

Corvus Pharmaceuticals has reported Total Current Liabilities over the past 4 years, most recently at $8.1 million for Q3 2025.

  • Quarterly results put Total Current Liabilities at $8.1 million for Q3 2025, down 82.6% from a year ago — trailing twelve months through Sep 2025 was $8.1 million (down 82.6% YoY), and the annual figure for FY2024 was $35.4 million, up 415.39%.
  • Total Current Liabilities for Q3 2025 was $8.1 million at Corvus Pharmaceuticals, down from $8.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CRVS hit a ceiling of $46.4 million in Q3 2024 and a floor of $6.7 million in Q1 2024.
  • Median Total Current Liabilities over the past 4 years was $9.3 million (2022), compared with a mean of $13.5 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 535.79% in 2024 and later crashed 82.6% in 2025.
  • Corvus Pharmaceuticals' Total Current Liabilities stood at $10.8 million in 2022, then plummeted by 36.11% to $6.9 million in 2023, then skyrocketed by 415.39% to $35.4 million in 2024, then plummeted by 77.19% to $8.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $8.1 million (Q3 2025), $8.5 million (Q2 2025), and $9.3 million (Q1 2025) per Business Quant data.